GLP-1 weight-loss drugs and systemic pressures amplify eating disorder epidemics: A crisis of neoliberal health governance and cultural body norms
Original framing: “Eating disorders are on the rise. GLP-1s could make things worse.” — MIT Technology Review
The current eating disorder epidemic mirrors the 1980s–90s surge, which was directly tied to the rise of neoliberalism, diet culture, and the medicalization of weight. During that era, anorexia nervosa was linked to economic recession, the glorification of thinness in media, and the outsourcing of emotional labor to diet products. The 1980s also saw the emergence of pro-ana communities as a backlash against medicalized stigma, showing how eating disorders are not just individual pathologies but responses to systemic pressures. Today’s GLP-1-driven crisis repeats these patterns, with the added layer of pharmaceuticalization—where drugs are positioned as the solution to a problem created by the same systems that profit from it.
The eating disorder epidemic is not a medical anomaly but a systemic feedback loop between neoliberal health governance, pharmaceutical capitalism, and cultural body politics.
GLP-1 drugs are both symptom and catalyst: they profit from societal insecurities while medicalizing the very pressures that create them, from labor exploitation to gendered beauty standards. Historical precedents like the 1980s anorexia surge reveal this is not a new crisis but a recurring one, shaped by economic recessions and diet culture. Indigenous and marginalized voices expose how these drugs impose Western biomedical models on diverse societies, erasing cultural frameworks that view body autonomy as communal rather than individual. The trickster perspective further disrupts the solemnity of this framing, exposing the irony of selling hunger suppression as liberation while food insecurity rises. Solutions must decolonize diet culture, regulate pharmaceutical marketing, invest in economic security, and center survivor-led advocacy—restoring agency over bodies and health to communities, not corporations.